IMPORTANCE Guidelines recommend consideration of chemotherapy for most patients with early-stage, estrogen receptor-positive, invasive breast cancer in the absence of additional prognostic information. The 21-gene recurrence score (RS) assay has been shown in limited academic settings to reduce physician recommendations for adjuvant chemotherapy. Associations between the adoption of the assay and receipt of chemotherapy in the general population have not been examined.
the relative benefits and risks of chemotherapy across risk groups. The Oncotype DX 21-gene recurrence score (RS) assay is an independent predictor of prognosis and the benefit of chemotherapy in tamoxifen-treated, ER-positive, node-negative breast cancer. [3] [4] [5] [6] [7] Several studies have suggested that use of the assay is cost saving or cost-effective, compared with conventional approaches, 6, [8] [9] [10] possibly as a result of more appropriate allocation of chemotherapy to patients most likely to benefit.
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Patients' treatment decisions can vary substantially depending on the patient's age, comorbid conditions, finances, and personal preferences and priorities. Studies of patients' treatment decisions after use of the RS assay have found that many patients do not follow guideline-based or physicianrecommended treatment. 2, 12, 13 In addition, even with a low or intermediate genomic risk score, many physicians may still be reluctant to withhold chemotherapy, particularly in younger patients. 2 Current evidence suggests that use of the RS assay reduces the likelihood of physicians recommending chemotherapy. 2, 6, 9, 12 However, it is unknown whether adoption of the assay has reduced overall chemotherapy use in the general population. Therefore, we examined associations between use of the RS assay and receipt of chemotherapy in a nationally representative cohort of patients who received a diagnosis of incident breast cancer between 2005 and 2009. We hypothesized that adoption of the assay was associated with lower odds of receiving chemotherapy.
Methods

Data Source
Data were from a Surveillance, Epidemiology, and End Results (SEER) and Medicare linked data set, a collaborative effort between the National Cancer Institute and the Centers for Medicare & Medicaid Services. The SEER data represent approximately 28% of the US population with cancer. 14 We used SEER data from 2005 through 2009 to identify patients' clinical and demographic characteristics. We used Medicare claims data from 2004 through 2010 to confirm Medicare enrollment and health care resource use. We used claims from the year before diagnosis to identify comorbid conditions. The institutional review board of the Duke University Health System approved this study. Informed consent was waived due to the retrospective nature of the study.
Study Population
We identified all patients who had a diagnosis of breast cancer between 2005 and 2009 in the 12 SEER registries that were continuously active from 2000 onward. To identify patients likely to have complete Medicare claims related to breast cancer management, we required that patients have a primary diagnosis of breast cancer (International Classification of Diseases, Ninth Revision, Clinical Modification code 174.x or 175.x) on an inpatient, outpatient, durable medical equipment, hospice, home health, or carrier-based Medicare claim between 2 months before and 4 months after the SEER-reported diagnosis. We included patients 66 years or older at diagnosis, except those whose diagnosis was made at autopsy. We excluded patients who had discontinuous Medicare Part A and Part B coverage (ie, fee-for-service Medicare) or were enrolled in Medicare Part C (managed care) from the year before diagnosis through the end of the study period or death. As a result, all patients in the study survived at least 1 year after initial breast cancer diagnosis. We also excluded patients with in situ disease because chemotherapy and use of the RS assay are not recommended for this group. We excluded patients with metastatic disease given the lack of RS assay utility in this group. We limited the analysis to patients with ER-positive tumors, in which the RS assay has been clinically validated and for which its use was initially recommended. Although the initial studies of the RS assay were limited to patients with node-negative disease, we previously observed use of the RS assay in nodepositive disease in this cohort, 15 and it has since been reported that the RS assay may predict disease-free and overall survival in these patients. 16 For these reasons, we elected to include patients with NCCN high-risk disease, including patients with node-positive disease, in our study.
Outcomes
The primary study outcome was receipt of chemotherapy (Current Procedural Terminology [CPT] code Q0083-Q0085, G0355-G0363, J8510-J9999, or 96400-96549) reported on any outpatient or carrier claim between 2 months before and 12 months after diagnosis. 17 The primary exposure of interest was use of the RS assay as reported on a carrier claim between 2 months before and 6 months after diagnosis. To identify claims for the RS assay, we rank-ordered each patient's claims containing CPT code 84999 (ie, unlisted chemistry procedure) from the highest to lowest payment amounts and by the claim date. We then retained the first record, which represented the most costly, earliest procedure. We reviewed these records manually to confirm that those with the highest payment in each year were performed by the same provider (eg, Genomic Health) and 
Statistical Analysis
We describe the baseline characteristics of the study population by year of diagnosis using frequencies and percentages for all variables. We used χ 2 tests to test for differences between groups. We used a multivariable logistic regression model to examine associations between use of the RS assay and receipt of chemotherapy. To minimize colinearity within the model, clinicopathologic factors included in the multivariable regression analysis were limited to grade, tumor size greater than 2.0 cm, and NCCN risk group. We did not include stage or nodal status because these are effectively captured by tumor size and NCCN risk variables. We conducted a prespecified subgroup analysis of patients aged 65 to 70 years to reduce confounding due to associations between age and use of the RS assay or receipt of chemotherapy. Significance tests and confidence intervals for estimates from all models were based on robust standard errors to account for the clustering of patients by registry. We used SAS, version 9.3 (SAS Institute), for all analyses. In addition to estimating overall associations, we estimated associations between use of the RS assay and receipt of chemotherapy in prespecified subgroups by adding a subgroup variable and an interaction term between the subgroup variable and the RS assay indicator to the models. We assessed differences between subgroups by testing the significance of the interaction term. We estimated the RS assay associations in each subgroup using model contrasts. Because of the multiple comparisons in this analysis, we report 99% confidence intervals and used α = .01 to establish statistical significance. All tests were 2 sided.
Sensitivity Analyses
To exclude the potential impact of immortal time bias and potential misclassification of chemotherapy in the adjuvant vs recurrent settings, we performed a sensitivity analysis that required all patients to survive 6 months after diagnosis, and we limited ascertainment of both the RS assay and chemotherapy to this same 6-month window. To address issues of selection bias associated with receipt of the RS assay, we also conducted a hospital referral region (HRR)-level analysis to examine associations between adoption of the RS assay and changes in chemotherapy use for the overall and younger than 70 years cohorts and provide a complementary populationbased perspective. 
Results
We identified 44 044 Medicare beneficiaries who received a diagnosis of ER-positive, nonmetastatic, invasive breast cancer in the SEER registries between 2005 and 2009. Table 1 shows the baseline characteristics of the study population stratified by use of the RS assay. Use of the assay was higher among patients 70 years or younger, patients with fewer comorbid conditions, and patients with T1c tumors, nodenegative disease, and intermediate-risk disease. eTables 1 through 4 in the Supplement show the baseline characteristics of the study population by risk category, receipt of chemotherapy, and use of the RS assay. Table 2 shows the baseline characteristics of the study population stratified by receipt of chemotherapy. Overall, 14.3% of patients received chemotherapy within 12 months after diagnosis. Among patients who had chemotherapy, more than 80% received it within 4 months after diagnosis. Among patients who underwent chemotherapy and testing with the RS assay, more than 90% received chemotherapy within 3 months after testing. Receipt of chemotherapy was more frequent in patients younger than 70 years, patients with fewer comorbid conditions, and patients with high-risk disease. Because of the strong dependence of chemotherapy use on patient age, we performed a prespecified analysis limiting the multivariable analyses to patients 70 years or younger (n = 11 135) ( Table 4 and eTable 6 in the Supplement). Similar to the primary analysis, we did not observe any association between use of the RS assay and use of chemotherapy (OR, 1.02 [99% CI, 0.81-1.28]). In univariate analysis, use of the assay was associated with decreased use of chemotherapy (OR, 0.65 [99% CI, 0.56-0.75]; P < .001). However, this association disappeared after adjustment for risk, suggesting that the association of the RS assay with chemotherapy in univariate models was largely confounded by risk. We also observed a steady (Figure) Sensitivity analyses limited to the 6-month window for chemotherapy and survival result in estimates nearly identical to those of the primary analysis. This suggests that neither immortal time bias nor the use of chemotherapy in patients with recurrent disease had any substantial impact on the results of the main analysis. Hospital referral region-level analysis comparing regional adoption of the RS assay and changes in overall chemotherapy use did not reveal significant associations between regional adoption of the RS assay and changes in chemotherapy use in the overall and younger than 70 years populations (eFigure in the Supplement). whether the patient resided in a census tract with the lowest quartile of education level defined by the proportion of the population that did not finish high school; the highest quartile of poverty defined by the proportion of the population below the poverty line; and the highest quartile of black population defined by the proportion of the population reporting black race.
Discussion
To our knowledge, ours is the first investigation of the association of use of the 21-gene RS assay and receipt of chemotherapy in a nationally representative sample of patients with early-stage, ER-positive breast cancer in community settings since the introduction of the RS assay in 2004. Contrary to our hypothesis, we did not observe a change in chemotherapy use in the overall study population after the adoption of the RS assay between 2005 and 2009 or a general association between receipt of chemotherapy and use of the assay in multivariable analyses or HRR-level analyses. However, there was a significant interaction between use of the assay and NCCN risk category. Use of the RS assay was associated with decreased chemotherapy use in high-risk patients and increased chemotherapy use in low-risk patients. Because of the substantial impact of age on the use of the RS assay and chemotherapy, we both node-negative and node-positive (ie, high-risk) patients from a total of 15 German medical centers before and after inclusion of RS assay results into their recommendation for chemotherapy. They found that assay results changed recommendations of a tumor board to exclude chemotherapy in 28% of patients and include chemotherapy in 9% of patients for node-positive disease, whereas the recommendations changed less drastically for node-negative disease (18% and 6%, respectively). 8 The RS assay risk scores in previous work have been associated with chemotherapy use of 10% (low RS), 36% (intermediate RS), and 72% (high RS), although no clinicopathologic correlates were available in these patients to help disambiguate the relative effect of assay risk score. 6 It should also be noted that much of the retrospective evidence regarding use of the RS assay and its impact on the use of chemotherapy did not emerge until after 2009. However, much of the key randomized and prospective evidence regarding use of the RS assay in ER-positive, node-negative disease was available for patients and physicians by the end of the study period. These studies included the major metaanalysis by the Early Breast Cancer Trialists Collaborative Group in 2005 demonstrating a benefit of chemotherapy in all women with early-stage disease, prospective prognostic (2004) and predictive (2006) validation of the RS assay, and guidelines that led to its recommended use by the American Society of Clinical Oncology by 2007. 3, [27] [28] [29] In most published clinical series, roughly half of patients had a low-risk RS, with median or mean ages in the mid-50s. It is unknown how the distribution of the RS from previous clinical series compares with patients in our study population, in which patients were on average at least a decade older. Overall rates of chemotherapy in our study were significantly lower than that reported rates of chemotherapy of roughly 40% in patients with ER-positive, node-negative disease who had the RS assay. In our sample, which included roughly 25% with node-positive disease, we observed 14.3% chemotherapy use among the overall population and 26.5% among patients 70 years or younger, which supports a significant influence of age on chemotherapy use. Although beyond the scope of this study, we previously reported details regarding the adoption of the RS assay in this population. 15 In our HRR-based sensitivity analyses, we confirmed Medicare reimbursement of the RS assay in all major HRRs included in the study by the end of the study period. Our study has some limitations. Only RS assays paid for by Medicare could be detected in the analysis. It is unlikely, but unknown, whether many RS assays among Medicare beneficiaries would be paid by third-party insurers or out of pocket. The claims-based approach used in this study to detect use of the RS assay has been described in detail by our group and others supporting the validity of using administrative claims data to detect use of the assay. 15, 30 We did not know the results of the assay, only that patients received the test. Any data or discussion of high-, intermediate-, and low-risk disease in this paper refers to NCCN risk categories. Patients in the SEER registry are overall more likely to be non-white and to live in low- An additional limitation of the data is that to our knowledge the RS assay risk score is currently not available for study within any nationally representative or population-level cohort, which would be needed to evaluate whether RS assay results are being used to appropriately guide the use of chemotherapy in individual patients. However, the goal of the present study was to examine to what extent adoption of the RS assay at the population or system level has influenced rates of chemotherapy, an effect that has been predicted but never empirically examined at the population level. Payers, policy makers, and institutions seeking to assess the impact of RS assay adoption on rates of chemotherapy use must make these decisions at the system level before knowing the results of the test. To address this question, we believe that the approach used in the present study, which remains agnostic as to the actual RS assay results, is the appropriate approach to evaluate the impact of RS assay adoption on chemotherapy use at the system or population level. Nonetheless, the extent to which the RS results are being used to guide chemotherapy within individual patients in the general population remains an important area of ongoing research.
Conclusions
Patient and clinicopathologic factors significantly influence receipt of chemotherapy and use of the RS assay in routine clinical practice. Previous studies suggested that use of the RS assay, depending on the patient population, may reduce overall chemotherapy rates by up to 20%. Our data suggest that use of the RS assay may have decreased chemotherapy use in general practice among younger patients with high-risk disease in whom receipt of chemotherapy would have otherwise been likely but that it was associated with greater chemotherapy use in patients with low-risk disease. The impact of the RS assay on chemotherapy use is likely population dependent and is influenced by the population's pretest likelihood of undergoing chemotherapy. The impact and association of RS assay adoption with costs and outcomes at the national level is an important area of future health policy breast cancer research.
